[Age- and weight-related dosage of dDAVP in the treatment of primary nocturnal enuresis].

摘要: BACKGROUND: In treating primary nocturnal enuresis the dosages recommended for an intranasal application of dDAVP are 20, 30 or 40 microgram depending on response. Dosages that take patient's weight age into account not commonly used until now. PATIENTS AND METHODS: present prospective study including 43 children therapeutic success was therefore evaluated basis dosage standardized according to both and patients. The patients' ranged from 16.5 98 kg, their 6 14.9 years. RESULTS: were applied 0.3 2.4 microgram/kg 3.74 15.3 x age/kg respectively. Therapeutic efficacy at 63 %. CONCLUSIONS: results suggest ideal weight-related 1 rather age- 8 weight/age. A higher evidently is little use since there a significant difference between non-responders responders (p < 0.01) with even reacting dosages.